Long-chain saturated fatty acids and its interaction with insulin resistance and the risk of nonalcoholic fatty liver disease in type 2 diabetes in Chinese

被引:8
|
作者
Jiang, Li-Peng [1 ]
Sun, Hong-Zhi [2 ,3 ]
机构
[1] Jinzhou Med Univ, Dept Radiat Oncol, Affiliated Hosp 1, Jinzhou, Peoples R China
[2] Jinzhou Med Univ, Dept Gen Surg, Affiliated Hosp 1, Jinzhou, Peoples R China
[3] Jinzhou Med Univ, Key Lab Liaoning Tumor Clin Metabol KLLTCM, Jinzhou, Peoples R China
来源
关键词
myristic acid (14:0); palmitic acid (16:0); IR; NAFLD; T2D; METABOLIC SYNDROME; PALMITIC ACID; MYRISTIC ACID; EPIDEMIOLOGY; ASSOCIATION; PREVALENCE; NAFLD; LIPOTOXICITY; DIAGNOSIS; PATHOLOGY;
D O I
10.3389/fendo.2022.1051807
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: This study aimed to explore relationships between long-chain saturated fatty acids (LSFAs) and nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes (T2D); and whether insulin action had an interactive effect with LSFAs on NAFLD progression. Methods: From April 2018 to April 2019, we extracted the electronic medical records of 481 patients with T2D who meet the inclusion and exclusion criteria from the Second Affiliated Hospital of Dalian Medical University. Ultrasound was used to estimate NAFLD at admission. Logistic regression analysis were used to estimate odds ratios (OR) and 95% confidence intervals (CI). The additive interaction was carried out to estimate interactions between LSFAs and insulin resistance (IR) in NAFLD patients with T2D. Results: Myristic acid (14:0) and palmitic add (16:0) were positively associated with the risk of NAFLD (OR for myristic acid (14:0): 7.516, 3.557-15.882 and OR for palmitic acid (16:0): 4.071, 1.987-8.343, respectively). After adjustment for traditional risk factors, these associations were slightly attenuated but still highly significant. Co-presence of myristic acid (14:0)>72.83 mu mol/L and IR>4.89 greatly increased OR of NAFLD to 9.691 (4.113-22.833). Similarly, copresence of palmitic acid (16:0)>3745.43 mu mol/L and IR>4.89 greatly increased OR of NAFLD to 6.518(2.860-14.854). However, stearic acid (18:0) and risk of NAFLD have no association. Moreover, there was no association between very-long-chain SFAs (VLSFAs) and risk of NAFLD. Discussion: Myristic acid (14:0) and palmitic acid (16:0) were positively associated with the risk of NAFLD in T2D patients in China. High IR amplified the effect of high myristic acid (14:0) and high palmitic acid (16:0) on NAFLD.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Very long-chain saturated fatty acids and diabetes and cardiovascular disease
    Lemaitre, Rozenn N.
    King, Irena B.
    CURRENT OPINION IN LIPIDOLOGY, 2022, 33 (01) : 76 - 82
  • [2] Nonalcoholic Fatty Liver Disease, Hepatic Insulin Resistance, and Type 2 Diabetes
    Birkenfeld, Andreas L.
    Shulman, Gerald I.
    HEPATOLOGY, 2014, 59 (02) : 713 - 723
  • [3] The therapeutic potential of long-chain omega-3 fatty acids in nonalcoholic fatty liver disease
    Shapiro, Haim
    Tehilla, Miryam
    Attal-Singer, Joelle
    Bruck, Rafael
    Luzzatti, Rachel
    Singer, Pierre
    CLINICAL NUTRITION, 2011, 30 (01) : 6 - 19
  • [4] Insulin Resistance in Type 2 Diabetes is Moderated by Saturated Fatty Acids
    Mezincescu, Alice M.
    Rudd, Amelia
    Cheyne, Lesley
    Horgan, Graham
    Philip, Sam
    Cameron, Donnie
    van Loon, Luc
    Whitfield, Philip
    Gribbin, Rachael
    Delibegovic, Mirela
    Fielding, Barbara
    Gray, Stuart
    Henning, Anke
    Dawson, Dana K.
    CIRCULATION, 2022, 146
  • [5] Long-chain fatty acids and cardiovascular disease risk in non-insulin-dependent diabetes
    Peterson, DB
    NUTRITION, 1998, 14 (03) : 316 - 318
  • [6] Serum Saturated Fatty Acids including Very Long-Chain Saturated Fatty Acids and Colorectal Cancer Risk among Chinese Population
    Wu, Qixin
    Shi, Dandan
    Dong, Ting
    Zhang, Zhuolin
    Ou, Qingjian
    Fang, Yujing
    Zhang, Caixia
    NUTRIENTS, 2023, 15 (08)
  • [7] Nonalcoholic fatty liver disease markers and insulin resistance in type 1 diabetes
    Duvnjak, L.
    Bulum, T.
    Kolaric, B.
    Duvnjak, M.
    DIABETOLOGIA, 2011, 54 : S245 - S245
  • [8] Treatment of Nonalcoholic Fatty Liver Disease with Long-Chain n-3 Polyunsaturated Fatty Acids in Humans
    Kelley, Nirvair S.
    METABOLIC SYNDROME AND RELATED DISORDERS, 2016, 14 (09) : 417 - 430
  • [9] The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease
    Fujii, Hideki
    Kawada, Norifumi
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (11)
  • [10] Long-chain saturated fatty acids consumption and risk of gallstone disease among men
    Tsai, Chung-Jyi
    Leitzmann, Michael F.
    Willett, Walter C.
    Giovannucci, Edward L.
    ANNALS OF SURGERY, 2008, 247 (01) : 95 - 103